DOWNLOADS AND LINKS

Resources

Tools to help support you during treatment with PADCEV®.

Download selected

Clear selection

English Patient and Caregiver Brochure

Learn about treatment with PADCEV.

English patient and caregiver brochure downloadable PDF.

English Patient and Caregiver Brochure

Learn about treatment with PADCEV.

Preview

PADCEV Discussion Guide and Symptom Tracker

A tool to help track your symptoms and guide conversations with your healthcare team.

PADCEV doctor discussion guide and symptom tracker downloadable PDF.

PADCEV Discussion Guide and Symptom Tracker

A tool to help track your symptoms and guide conversations with your healthcare team.

Preview

More resources for you

Additional Resources

Dr Joe Explains: Metastatic Bladder Cancer

Tips and tools to help you take control of your experience.

Dr. Joe Explains: Metastatic Bladder Cancer downloadable PDF.

Dr Joe Explains: Metastatic Bladder Cancer

Tips and tools to help you take control of your experience.

Preview

Metastatic Bladder Cancer

Tips and tools to help you take control of your cancer experience.

Preview

Select to download

Other Advocacy and Support Resources

There are many groups and organizations dedicated to providing help for you and your loved ones. The following may be able to help.

Astellas and Seagen are not affiliated with and do not endorse any of the listed organizations. The information provided is for informational purposes only and is not meant to replace the advice of a healthcare professional.

These advocacy support groups are included as a reference for patients and caregivers. Their inclusion does not imply endorsement from the individual advocacy support groups listed.

Bladder Cancer Advocacy Network
bcan.org

Cancer Support Community
cancersupportcommunity.org/bladder-cancer

CancerCare
cancercare.org

Triage Cancer
triagecancer.org

Cancer + Careers
cancerandcareers.org/en

Please see full Prescribing Information/Patient Information for more information, including risk of Serious Side Effects.

Back to top

IMPORTANT SAFETY INFORMATION/
WHAT IS PADCEV®?

What is the most important information I should know about PADCEV?

PADCEV may cause serious side effects, including:

Skin reactions. Skin reactions including severe skin reactions have happened in people treated with PADCEV and may be more common when PADCEV is given with pembrolizumab. In some cases, these severe skin reactions have caused death. Most severe skin reactions occurred during the first cycle of treatment but may happen later. Your healthcare provider will monitor you, may stop your treatment with PADCEV completely or for a period of time (temporarily), may change your dose, and may prescribe medicines if you get skin reactions. Tell your healthcare provider right away if you develop any of these signs of a new or worsening skin reaction:

target lesions (skin reactions that look like rings)

rash or itching that continues to get worse

blistering or peeling of the skin

painful sores or ulcers in mouth or nose, throat, or genital area

fever or flu-like symptoms

swollen lymph nodes

See “What are the possible side effects of PADCEV?” for more information about side effects.

PADCEV Important Safety Information icon.

Before receiving PADCEV, tell your healthcare provider about all of your medical conditions, including if you:

are currently experiencing numbness or tingling in your hands or feet.

have a history of high blood sugar or diabetes.

have liver problems.

are pregnant or plan to become pregnant. PADCEV can harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with PADCEV.

are breastfeeding or plan to breastfeed. It is not known if PADCEV passes into your breast milk. Do not breastfeed during treatment and for at least 3 weeks after the last dose of PADCEV.

Pregnancy warning for females icon.

Females who are able to become pregnant:

Your healthcare provider should do a pregnancy test before you start treatment with PADCEV.

You should use an effective method of birth control during your treatment and for at least 2 months after the last dose of PADCEV.

Pregnancy warning for male partners icon.

Males with a female sexual partner who is able to become pregnant:

If your female partner is pregnant, PADCEV can harm the unborn baby.

You should use an effective method of birth control during your treatment and for at least 4 months after the last dose of PADCEV.

Drug interactions icon.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking PADCEV with certain other medicines may cause side effects.

What are the possible side effects of PADCEV?

PADCEV may cause serious side effects, including:

Skin reactions icon.

Skin Reactions. See “What is the most important information I should know about PADCEV?”

High blood sugar icon.

High blood sugar (hyperglycemia). An increase in blood sugar is common during treatment with PADCEV. Severe high blood sugar, a serious condition called diabetic ketoacidosis (DKA), and death have happened in people with and without diabetes treated with PADCEV. Tell your healthcare provider right away if you have any symptoms of high blood sugar, including: frequent urination, increased thirst, blurred vision, confusion, it becomes harder to control your blood sugar, drowsiness, loss of appetite, fruity smell on your breath, nausea, vomiting, or stomach pain.

Lung problems icon.

Lung problems. PADCEV may cause severe or life-threatening inflammation of the lungs that can lead to death. These severe problems may happen more often when PADCEV is given in combination with pembrolizumab. Tell your healthcare provider right away if you get new or worsening symptoms, including trouble breathing, shortness of breath, or cough.

Hand with peripheral neuropathy icon.

Nerve problems. Nerve problems called peripheral neuropathy are common during treatment with PADCEV and can sometimes be severe. Nerve problems may happen more often when PADCEV is given in combination with pembrolizumab. Tell your healthcare provider right away if you get new or worsening numbness or tingling in your hands or feet or muscle weakness.

Eye problems icon.

Eye problems. Certain eye problems are common during treatment with PADCEV. Tell your healthcare provider right away if you have dry eyes, increased tearing, blurred vision, or any vision changes. You may use artificial tear substitutes to help prevent or treat dry eyes.

Infusion site (extravasation) icon.

Leakage of PADCEV out of your vein into the tissues around your infusion site (extravasation). If PADCEV leaks from the injection site or the vein into the nearby skin and tissues, it could cause an infusion site reaction. These reactions can happen right after you receive an infusion, but sometimes may happen days after your infusion. Tell your healthcare provider or get medical help right away if you notice any redness, swelling, itching, blister, peeling skin or discomfort at the infusion site.

Your healthcare provider may decrease your dose of PADCEV, or temporarily or completely stop your treatment with PADCEV if you have severe side effects.

The most common side effects of PADCEV when used alone include:

rash. See “What is the most important information I should know about PADCEV?”

changes in liver and kidney function tests

increased sugar (glucose) in the blood. See “High blood sugar (hyperglycemia)”

tiredness

decreased white blood cell, red blood cell, and platelet counts

hair loss

decreased appetite

diarrhea

decreased sodium, phosphate and protein (albumin) in the blood

nausea

itching

change in sense of taste

increased uric acid in the blood

increased lipase (a test done to check your pancreas)

decreased weight

dry skin

If your healthcare provider prescribes PADCEV in combination with pembrolizumab for you, also read the Medication Guide that comes with pembrolizumab for important information about pembrolizumab.

The most common side effects of PADCEV when used in combination with pembrolizumab include:

increased sugar (glucose) in the blood. See “High blood sugar (hyperglycemia)”

changes in liver and kidney function tests

rash. See “What is the most important information I should know about PADCEV?”

decreased red blood cell and white blood cell counts

tiredness

decreased sodium, phosphate and protein (albumin) in the blood

increased lipase (a test done to check your pancreas)

hair loss

decreased weight

diarrhea

itching

decreased appetite

nausea

change in sense of taste

urinary tract infection

constipation

increased or decreased potassium

increased calcium in the blood

swelling of the arms, hands, legs and feet

dry eye. See “Eye problems”

dizziness

joint aches

dry skin


PADCEV may cause fertility problems in females and males, which may affect the ability to have children. Talk to your healthcare provider if you have concerns about fertility.

These are not all the possible side effects of PADCEV.

Communicate with your doctor icon.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

WHAT IS PADCEV®?

PADCEV is a prescription medicine used to treat adults with bladder cancer and cancers of the urinary tract (renal pelvis, ureter or urethra) that has spread or cannot be removed by surgery. PADCEV may be used alone if you:

have received an immunotherapy medicine and chemotherapy that contains platinum, or

are not able to receive a chemotherapy that contains the medicine cisplatin and you have received 1 or more prior therapy.

PADCEV may be used with pembrolizumab (also known as Keytruda®) if you:

are not able to receive a chemotherapy that contains the medicine cisplatin.

It is not known if PADCEV is safe and effective in children.

PADCEV with pembrolizumab was FDA approved based on a clinical study that measured how many people had a tumor response. There is another study of PADCEV with pembrolizumab to confirm the clinical benefit.

Please see full Prescribing Information/Patient Information for more information, including risk of Serious Side Effects.


IMPORTANT SAFETY INFORMATION/
WHAT IS PADCEV®?

What is the most important information I should know about PADCEV?

PADCEV may cause serious side effects, including:

Skin reactions. Skin reactions including severe skin reactions have happened in people treated with PADCEV and may be more common when PADCEV is given with pembrolizumab. In some cases, these severe skin reactions have caused death. Most severe skin reactions occurred during the first cycle of treatment but may happen later. Your healthcare provider will monitor you, may stop your treatment with PADCEV completely or for a period of time (temporarily), may change your dose, and may prescribe medicines if you get skin reactions. Tell your healthcare provider right away if you develop any of these signs of a new or worsening skin reaction:

target lesions (skin reactions that look like rings)

rash or itching that continues to get worse

blistering or peeling of the skin

painful sores or ulcers in mouth or nose, throat, or genital area

fever or flu-like symptoms

swollen lymph nodes

See “What are the possible side effects of PADCEV?” for more information about side effects.

PADCEV Important Safety Information icon.

Before receiving PADCEV, tell your healthcare provider about all of your medical conditions, including if you:

are currently experiencing numbness or tingling in your hands or feet.

have a history of high blood sugar or diabetes.

have liver problems.

are pregnant or plan to become pregnant. PADCEV can harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with PADCEV.

are breastfeeding or plan to breastfeed. It is not known if PADCEV passes into your breast milk. Do not breastfeed during treatment and for at least 3 weeks after the last dose of PADCEV.

Pregnancy warning for females icon.

Females who are able to become pregnant:

Your healthcare provider should do a pregnancy test before you start treatment with PADCEV.

You should use an effective method of birth control during your treatment and for at least 2 months after the last dose of PADCEV.

Pregnancy warning for male partners icon.

Males with a female sexual partner who is able to become pregnant:

If your female partner is pregnant, PADCEV can harm the unborn baby.

You should use an effective method of birth control during your treatment and for at least 4 months after the last dose of PADCEV.

Drug interactions icon.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking PADCEV with certain other medicines may cause side effects.

What are the possible side effects of PADCEV?

PADCEV may cause serious side effects, including:

Skin reactions icon.

Skin Reactions. See “What is the most important information I should know about PADCEV?”

High blood sugar icon.

High blood sugar (hyperglycemia). An increase in blood sugar is common during treatment with PADCEV. Severe high blood sugar, a serious condition called diabetic ketoacidosis (DKA), and death have happened in people with and without diabetes treated with PADCEV. Tell your healthcare provider right away if you have any symptoms of high blood sugar, including: frequent urination, increased thirst, blurred vision, confusion, it becomes harder to control your blood sugar, drowsiness, loss of appetite, fruity smell on your breath, nausea, vomiting, or stomach pain.

Lung problems icon.

Lung problems. PADCEV may cause severe or life-threatening inflammation of the lungs that can lead to death. These severe problems may happen more often when PADCEV is given in combination with pembrolizumab. Tell your healthcare provider right away if you get new or worsening symptoms, including trouble breathing, shortness of breath, or cough.

Hand with peripheral neuropathy icon.

Nerve problems. Nerve problems called peripheral neuropathy are common during treatment with PADCEV and can sometimes be severe. Nerve problems may happen more often when PADCEV is given in combination with pembrolizumab. Tell your healthcare provider right away if you get new or worsening numbness or tingling in your hands or feet or muscle weakness.

Eye problems icon.

Eye problems. Certain eye problems are common during treatment with PADCEV. Tell your healthcare provider right away if you have dry eyes, increased tearing, blurred vision, or any vision changes. You may use artificial tear substitutes to help prevent or treat dry eyes.

Infusion site (extravasation) icon.

Leakage of PADCEV out of your vein into the tissues around your infusion site (extravasation). If PADCEV leaks from the injection site or the vein into the nearby skin and tissues, it could cause an infusion site reaction. These reactions can happen right after you receive an infusion, but sometimes may happen days after your infusion. Tell your healthcare provider or get medical help right away if you notice any redness, swelling, itching, blister, peeling skin or discomfort at the infusion site.

Your healthcare provider may decrease your dose of PADCEV, or temporarily or completely stop your treatment with PADCEV if you have severe side effects.

The most common side effects of PADCEV when used alone include:

rash. See “What is the most important information I should know about PADCEV?”

changes in liver and kidney function tests

increased sugar (glucose) in the blood. See “High blood sugar (hyperglycemia)”

tiredness

decreased white blood cell, red blood cell, and platelet counts

hair loss

decreased appetite

diarrhea

decreased sodium, phosphate and protein (albumin) in the blood

nausea

itching

change in sense of taste

increased uric acid in the blood

increased lipase (a test done to check your pancreas)

decreased weight

dry skin

If your healthcare provider prescribes PADCEV in combination with pembrolizumab for you, also read the Medication Guide that comes with pembrolizumab for important information about pembrolizumab.

The most common side effects of PADCEV when used in combination with pembrolizumab include:

increased sugar (glucose) in the blood. See “High blood sugar (hyperglycemia)”

changes in liver and kidney function tests

rash. See “What is the most important information I should know about PADCEV?”

decreased red blood cell and white blood cell counts

tiredness

decreased sodium, phosphate and protein (albumin) in the blood

increased lipase (a test done to check your pancreas)

hair loss

decreased weight

diarrhea

itching

decreased appetite

nausea

change in sense of taste

urinary tract infection

constipation

increased or decreased potassium

increased calcium in the blood

swelling of the arms, hands, legs and feet

dry eye. See “Eye problems”

dizziness

joint aches

dry skin


PADCEV may cause fertility problems in females and males, which may affect the ability to have children. Talk to your healthcare provider if you have concerns about fertility.

These are not all the possible side effects of PADCEV.

Communicate with your doctor icon.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

WHAT IS PADCEV®?

PADCEV is a prescription medicine used to treat adults with bladder cancer and cancers of the urinary tract (renal pelvis, ureter or urethra) that has spread or cannot be removed by surgery. PADCEV may be used alone if you:

have received an immunotherapy medicine and chemotherapy that contains platinum, or

are not able to receive a chemotherapy that contains the medicine cisplatin and you have received 1 or more prior therapy.

PADCEV may be used with pembrolizumab (also known as Keytruda®) if you:

are not able to receive a chemotherapy that contains the medicine cisplatin.

It is not known if PADCEV is safe and effective in children.

PADCEV with pembrolizumab was FDA approved based on a clinical study that measured how many people had a tumor response. There is another study of PADCEV with pembrolizumab to confirm the clinical benefit.

Please see full Prescribing Information/Patient Information for more information, including risk of Serious Side Effects.


IMPORTANT SAFETY INFORMATION/
WHAT IS PADCEV®?

What is the most important information I should know about PADCEV?

PADCEV may cause serious side effects, including:

Skin reactions. Skin reactions including severe skin reactions have happened in people treated with PADCEV and may be more common when PADCEV is given with pembrolizumab. In some cases, these severe skin reactions have caused death. Most severe skin reactions occurred during the first cycle of treatment but may happen later. Your healthcare provider will monitor you, may stop your treatment with PADCEV completely or for a period of time (temporarily), may change your dose, and may prescribe medicines if you get skin reactions. Tell your healthcare provider right away if you develop any of these signs of a new or worsening skin reaction:

target lesions (skin reactions that look like rings)

rash or itching that continues to get worse

blistering or peeling of the skin

painful sores or ulcers in mouth or nose, throat, or genital area

fever or flu-like symptoms

swollen lymph nodes

See “What are the possible side effects of PADCEV?” for more information about side effects.

PADCEV Important Safety Information icon.

Before receiving PADCEV, tell your healthcare provider about all of your medical conditions, including if you:

are currently experiencing numbness or tingling in your hands or feet.

have a history of high blood sugar or diabetes.

have liver problems.

are pregnant or plan to become pregnant. PADCEV can harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with PADCEV.

are breastfeeding or plan to breastfeed. It is not known if PADCEV passes into your breast milk. Do not breastfeed during treatment and for at least 3 weeks after the last dose of PADCEV.

Pregnancy warning for females icon.

Females who are able to become pregnant:

Your healthcare provider should do a pregnancy test before you start treatment with PADCEV.

You should use an effective method of birth control during your treatment and for at least 2 months after the last dose of PADCEV.

Pregnancy warning for male partners icon.

Males with a female sexual partner who is able to become pregnant:

If your female partner is pregnant, PADCEV can harm the unborn baby.

You should use an effective method of birth control during your treatment and for at least 4 months after the last dose of PADCEV.

Drug interactions icon.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking PADCEV with certain other medicines may cause side effects.

What are the possible side effects of PADCEV?

PADCEV may cause serious side effects, including:

Skin reactions icon.

Skin Reactions. See “What is the most important information I should know about PADCEV?”

High blood sugar icon.

High blood sugar (hyperglycemia). An increase in blood sugar is common during treatment with PADCEV. Severe high blood sugar, a serious condition called diabetic ketoacidosis (DKA), and death have happened in people with and without diabetes treated with PADCEV. Tell your healthcare provider right away if you have any symptoms of high blood sugar, including: frequent urination, increased thirst, blurred vision, confusion, it becomes harder to control your blood sugar, drowsiness, loss of appetite, fruity smell on your breath, nausea, vomiting, or stomach pain.

Lung problems icon.

Lung problems. PADCEV may cause severe or life-threatening inflammation of the lungs that can lead to death. These severe problems may happen more often when PADCEV is given in combination with pembrolizumab. Tell your healthcare provider right away if you get new or worsening symptoms, including trouble breathing, shortness of breath, or cough.

Hand with peripheral neuropathy icon.

Nerve problems. Nerve problems called peripheral neuropathy are common during treatment with PADCEV and can sometimes be severe. Nerve problems may happen more often when PADCEV is given in combination with pembrolizumab. Tell your healthcare provider right away if you get new or worsening numbness or tingling in your hands or feet or muscle weakness.

Eye problems icon.

Eye problems. Certain eye problems are common during treatment with PADCEV. Tell your healthcare provider right away if you have dry eyes, increased tearing, blurred vision, or any vision changes. You may use artificial tear substitutes to help prevent or treat dry eyes.

Infusion site (extravasation) icon.

Leakage of PADCEV out of your vein into the tissues around your infusion site (extravasation). If PADCEV leaks from the injection site or the vein into the nearby skin and tissues, it could cause an infusion site reaction. These reactions can happen right after you receive an infusion, but sometimes may happen days after your infusion. Tell your healthcare provider or get medical help right away if you notice any redness, swelling, itching, blister, peeling skin or discomfort at the infusion site.

Your healthcare provider may decrease your dose of PADCEV, or temporarily or completely stop your treatment with PADCEV if you have severe side effects.

The most common side effects of PADCEV when used alone include:

rash. See “What is the most important information I should know about PADCEV?”

changes in liver and kidney function tests

increased sugar (glucose) in the blood. See “High blood sugar (hyperglycemia)”

tiredness

decreased white blood cell, red blood cell, and platelet counts

hair loss

decreased appetite

diarrhea

decreased sodium, phosphate and protein (albumin) in the blood

nausea

itching

change in sense of taste

increased uric acid in the blood

increased lipase (a test done to check your pancreas)

decreased weight

dry skin

If your healthcare provider prescribes PADCEV in combination with pembrolizumab for you, also read the Medication Guide that comes with pembrolizumab for important information about pembrolizumab.

The most common side effects of PADCEV when used in combination with pembrolizumab include:

increased sugar (glucose) in the blood. See “High blood sugar (hyperglycemia)”

changes in liver and kidney function tests

rash. See “What is the most important information I should know about PADCEV?”

decreased red blood cell and white blood cell counts

tiredness

decreased sodium, phosphate and protein (albumin) in the blood

increased lipase (a test done to check your pancreas)

hair loss

decreased weight

diarrhea

itching

decreased appetite

nausea

change in sense of taste

urinary tract infection

constipation

increased or decreased potassium

increased calcium in the blood

swelling of the arms, hands, legs and feet

dry eye. See “Eye problems”

dizziness

joint aches

dry skin


PADCEV may cause fertility problems in females and males, which may affect the ability to have children. Talk to your healthcare provider if you have concerns about fertility.

These are not all the possible side effects of PADCEV.

Communicate with your doctor icon.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

WHAT IS PADCEV®?

PADCEV is a prescription medicine used to treat adults with bladder cancer and cancers of the urinary tract (renal pelvis, ureter or urethra) that has spread or cannot be removed by surgery. PADCEV may be used alone if you:

have received an immunotherapy medicine and chemotherapy that contains platinum, or

are not able to receive a chemotherapy that contains the medicine cisplatin and you have received 1 or more prior therapy.

PADCEV may be used with pembrolizumab (also known as Keytruda®) if you:

are not able to receive a chemotherapy that contains the medicine cisplatin.

It is not known if PADCEV is safe and effective in children.

PADCEV with pembrolizumab was FDA approved based on a clinical study that measured how many people had a tumor response. There is another study of PADCEV with pembrolizumab to confirm the clinical benefit.

Please see full Prescribing Information/Patient Information for more information, including risk of Serious Side Effects.


© 2023 Astellas Pharma US, Inc. and Seagen Inc. All rights reserved. 081-1008-PM 07/23
PADCEV® and the PADCEV device are trademarks jointly owned by Agensys, Inc., and Seagen Inc.
Astellas and the flying star logo are registered trademarks of Astellas Pharma Inc.
Seagen and the Seagen logo are registered trademarks of Seagen Inc.
PADCEV Support SolutionsSM, a component of Astellas Pharma Support SolutionsSM, is a service mark jointly owned by Agensys, Inc., and Seagen Inc.
Keytruda® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
All other marks referenced herein are the property of their respective owners.


© 2023 Astellas Pharma US, Inc. and Seagen Inc. All rights reserved. 081-1008-PM 07/23
PADCEV® and the PADCEV device are trademarks jointly owned by Agensys, Inc., and Seagen Inc.
Astellas and the flying star logo are registered trademarks of Astellas Pharma Inc.
Seagen and the Seagen logo are registered trademarks of Seagen Inc.
PADCEV Support SolutionsSM, a component of Astellas Pharma Support SolutionsSM, is a service mark jointly owned by Agensys, Inc., and Seagen Inc.
Keytruda® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
All other marks referenced herein are the property of their respective owners.

© 2023 Astellas Pharma US, Inc. and Seagen Inc. All rights reserved. 081-1008-PM 07/23
PADCEV® and the PADCEV device are trademarks jointly owned by Agensys, Inc., and Seagen Inc.
Astellas and the flying star logo are registered trademarks of Astellas Pharma Inc.
Seagen and the Seagen logo are registered trademarks of Seagen Inc.
PADCEV Support SolutionsSM, a component of Astellas Pharma Support SolutionsSM, is a service mark jointly owned by Agensys, Inc., and Seagen Inc.
Keytruda® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
All other marks referenced herein are the property of their respective owners.


© 2023 Astellas Pharma US, Inc. and Seagen Inc. All rights reserved. 081-1008-PM 07/23
PADCEV® and the PADCEV device are trademarks jointly owned by Agensys, Inc., and Seagen Inc.
Astellas and the flying star logo are registered trademarks of Astellas Pharma Inc.
Seagen and the Seagen logo are registered trademarks of Seagen Inc.
PADCEV Support SolutionsSM, a component of Astellas Pharma Support SolutionsSM, is a service mark jointly owned by Agensys, Inc., and Seagen Inc.
Keytruda® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
All other marks referenced herein are the property of their respective owners.